Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020091512 - PHARMACEUTICAL COMPOSITION FOR USE IN TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY

Publication Number WO/2020/091512
Publication Date 07.05.2020
International Application No. PCT/KR2019/014726
International Filing Date 01.11.2019
IPC
A61K 31/4164 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41641,3-Diazoles
A61K 45/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 9/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
Applicants
  • (주)셀트리온 CELLTRION INC. [KR]/[KR]
Inventors
  • 남궁훈 NAMKOONG, Hoon
  • 김본중 KIM, Bon Joong
  • 이보람 LEE, Bo Ram
  • 최은선 CHOI, Eun Sun
Priority Data
10-2018-013395802.11.2018KR
Publication Language Korean (KO)
Filing Language Korean (KO)
Designated States
Title
(EN) PHARMACEUTICAL COMPOSITION FOR USE IN TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
(FR) COMPOSITION PHARMACEUTIQUE DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT DE LA CARDIOMYOPATHIE HYPERTROPHIQUE
(KO) 비후성 심근증 치료용 약학 조성물
Abstract
(EN)
The present invention relates to a pharmaceutical composition comprising cibenzoline, especially, S(-)-cibenzoline or a pharmaceutically acceptable salt thereof as an active ingredient for treatment of hypertrophic cardiomyopathy, and a method for treatment of hypertrophic cardiomyopathy by using same. The treatment composition and method according to the present invention is used to treat a patient suffering from hypertrophic cardiomyopathy. In addition, the composition and method according to the present invention has excellent efficacy and safety, compared to conventional off-label standard of care (SOC).
(FR)
La présente invention concerne une composition pharmaceutique comprenant une cibenzoline, en particulier la S(-)-cibenzoline ou un sel pharmaceutiquement acceptable de celle-ci en tant que principe actif pour le traitement de la cardiomyopathie hypertrophique, et un procédé de traitement de la cardiomyopathie hypertrophique à l'aide de celle-ci. La composition et le procédé de traitement selon la présente invention sont utilisés pour traiter un patient souffrant d'une cardiomyopathie hypertrophique. De plus, la composition et le procédé selon la présente invention ont une efficacité et une sécurité excellentes, par comparaison avec une norme de soin (SOC) hors AMM classique.
(KO)
본 발명은 시벤졸린(Cibenzoline)을 특히 S(-)-시벤졸린 또는 이의 약제학적으로 허용되는 염을 유효성분으로 포함하는 비후성 심근증 치료용 약학 조성물 및 이를 이용한 비후성 심근증 치료 방법에 관한 것이다. 본 발명에 따른 치료용 조성물 및 방법은 비후성 심근증 환자를 치료한다. 또한 본 발명에 따른 조성물 및 방법은 기존 오프-라벨 치료 방법과 대비하여 우수한 유효성 및 안전성을 가진다.
Latest bibliographic data on file with the International Bureau